Cornpops

List of Biochemicals Stocks

Biochemicals stocks are publicly traded companies whose business involves using plant or animal based feedstocks (biomass) to create new chemicals or substitutes of existing petrochemicals, plastics, or other fossil fuel derived substances other than fuels. Amyris (AMRS) BioAmber (BIOA) Codexis (CDXS) Eastman Chemical Company (EMN) Global Bioenergies (ALGBE: EURONEXT) Novozymes (Copenhagen:NZYM-B; OTC:NVZMY) If you know of any biochemicals stock that is not listed here and should be, please let us know by leaving a comment. Also for stocks in the list that you think should be removed.
biopolymer teabags

Investing in Biopolymers

Last month Eastman Chemical Company (EMN:  NYSE) announced an expansion of its urethane extrusion line at one of its specialty chemical plants. This one located near Martinsville, Virginia makes paint protection films and window films.  Urethane is perfect to protect surfaces in a home or business.  It is not brittle like plastic, but has excellent tolerance for grease and oils.  When exposed to the elements it does not rot or degrade over time like rubber. Shareholders likely cheered the development in Virginia for potential addition to market share.  Eastman grabbed $9.6 billion in sales from the specialty chemicals market in 2017, earning $1.4 billion in net income or...

Countdown To Codexis’ Day Of Reckoning

It is earnings season and bio-catalyst developer Codexis (CDXS:  Nasdaq) is expected to report fourth quarter and year-end 2017 financial results in the coming weeks.  The three analysts who regularly publish estimates for the company expect a nickel profit in the quarter on $23 million in total sales of the company’s custom protein catalysts.  Codexis is still perfecting its proprietary platform technology called CodeEvolver, but has already delivered an array of unique enzymes that help drive critical biological processes for its customers. Codexis does not have a good track record in terms of meeting the consensus estimate.  The company has only cleared the...

BioAmber Gets Little Love From Investors on Valentine’s Day

by Debra Fiakas Management of sustainable chemical developer BioAmber (BIOA:  NYSE; BIOA:  TSX) have not been feeling much love from the capital markets.  The BioAmber team just wants some consideration for its proprietary platform for production of bio-based succinic acid.  Historically succinic acid has been produced from fossil fuel and sold as an intermediate input for use in drug compounds, agriculture and food production.  BioAmber has fine tuned a fermentation process to transform organic materials such as dextrose sugars into a bio-succinic acid. BioAmber’s woes began last fall when the New York Stock Exchange sent the company a notice of non-compliance with NYSE...

Novozymes Ignites Yeast Wars

Novozymes (Copenhagen:NZYM-B; OTC:NVZMY) moved into yeast this week with a new organism, Innova Drive. It’s saccharomyces cerevisae — the workhouse yeast that has been powering wine fermentation since the days of Noah and the Ark. But here’s a new strain engineered to cut fermentation times up to two hours, and yield boosts of up to two percent. A 2% yield increase and a 5% faster rate of production — let’s illustrate it — would mean something like 7.1 million gallons per year of more ethanol from the same standard 100 million gallon nameplate plant. Retailing at up to $10 million dollars, per year (yes,...

Beets to Gas

by Debra Fiakas, CFA In recent weeks management from Global Bioenergies (ALGBE: EURONEXT)made the rounds among New York City investors. The French specialty chemical developer is trying to win new friends in the U.S. for its bio-isobutene made through the fermentation of organic materials. Isobutene, also called isobutylene, is a four-molecule hydrocarbon that is a foundational chemical in a wide range of common products from gasoline additives to cosmetics. Until recently, isobutene was made exclusively in the crude oil refinement process. It is one of the many by-products of crude oil refining that helps pad the profit margins of big oil...

Biofuels M&A: 2017 Review and Outlook

by Bruce Comer, Ocean Park Advisors More industry players chose to develop and build new capacity rather than buy plants The North American biofuels industry experienced the fewest merger and acquisition transactions in recent history in 2017. There were only six M&A transactions, with a total estimated value of more than $100 million. They involved eight plants with 297 million gallons per year (MGPY) of production capacity. Half of these deals were for non-operating plants. A fourth deal was for a sub-scale demonstration plant. Contributing to the limited deal flow, two historically active acquirers, Green Plains and REG, did not close...

A Decade Of Unexpected Curves In The Bioeconomy

By Jim Lane Over the years we’ve all seen a lot of curveballs in the advanced bioeconomy. You see companies like Valero, which lobby the United States Congress with unbridled intensity to get rid of the Renewable Fuel Standard, on the verge of becoming the single-biggest producer of RINs in the United States (with news that they might take capacity at Diamond Green Diesel up to 540 million gallons). You see companies like Solazyme which love the Renewable Fuel Standard and drive up to nearly a billion-dollar post-IPO valuation based on delivering fuels at volume, then announcing that there are even...

Corbion Bids To Acquire TerraVia

Corbion Bids To Acquire TerraVia In California, Corbion has made a $20M stalking horse stock and asset purchase bid for TerraVia (TRVA). The purchase agreement provides TerraVia with a binding bid of $20 million in cash along with the assumption of certain liabilities, which is subject to higher or otherwise better offers. As part of the transaction, Corbion will be assuming the ongoing financial obligations of the business and its joint venture ownership, therefore the total financial commitment is expected to be in excess of the cash purchase price. Through this proposed transaction, TerraVia employees, who bring with them a wide...

Amyris: 90 Days To Build The Future

Jim Lane In California, Amyris (AMRS) reported Q1 revenues of $13.0M compared with $8.8M for Q1 2016, and touted the “significant increase in product sales, primarily in the personal care and health and nutrition markets, offset by a slight decline in collaboration revenue.” Collaboration revenues contributed $4.7M and product sales added $8.3M for the quarter. Big Q1 miss vs analyst expectations As Jeff Osborne at Cowen & Co noted, “Amyris reported revenue of $13.0mn, well below our estimate of $37.1mn due to much lower collaboration payments than we had anticipated. Management has highlighted that these payments can...

Amyris Boards The Sweet Fleet

Jim Lane Back in September 2015, we reported that Amyris inked a multi-year agreement with the US Defense Advance Research Projects Agency, the famed DARPA that gave us everything from kevlar to the Global Positioning System and the Internet the goal in this $35M agreement with the Biological Technologies Office was to create new research and development tools and technologies compressing the time to market for any new molecule by at least 10-fold in both time and cost. The story expanded this week when we heard from Amyris (AMRS) that it had completed strain engineering and...

New Bio-Based Tacky Resins Launched With Amyris Technology

Jim Lane In France, Cray Valley has launched new tackifying resins produced with Amyris’ (AMRS) biologically derived Biofene branded farnesene. Tack is the measure of stickiness vital to everything from adhesives that need to hold things in place to inks that need to stay on the printed page. According to independent market research firm, MarketsandMarkets.com, the global tackifier market is projected to reach USD 3.56 billion by 2020. This poses a large opportunity for renewable farnesene-based tackifiers and Amyris believes it can access a large market share as its product applications within the space achieve commercial scale. Cray...

Avantium IPO “Many Times Oversubscribed:” What Buyers Are So Excited About

Jim Lane  In France, Avantium completed its highly-anticipated initial public offering, raising $109.5M (€103M) via the sale of 9,401,793 shares at $11.70 (€11) per share, giving the company a market capitalization reaches of $294M (€277M). Trading will begin on March 15th 2017 on Euronext Amsterdam and Euronext Bruxelles under the symbol AVTX. The Company anticipates to use €65-75 million of the net proceeds of the Offering for the funding of the Joint Venture, enabling it to construct and operate the reference plant for the commercialization of the YXY technology. The company’s first world-scale plant is a 50,000 tons...

Bioplastics Maker Avantium’s IPO Plans

Jim Lane Here’s our 10-minute version of the filing, slightly re-organized to make sense to Earthlings instead of aliens from the Planet Prospectus. In the Netherlands, bioplastics maker Avantium is planning an initial public offering and listing of all shares on Euronext Amsterdam and Euronext Brussels. The company expects to raise up to €100 million (USD$106 million) and complete the offering by the end of the current quarter. More than half of the offering has already been secured via commitments from cornerstone investors. Avantium’s YXY technology converts plant-based sugar into chemicals and plastics, including 2,5-furandicarboxylic acid, a precursor...

BioAmber Launching Asian Joint Venture

Amber Waves of Gain In South Korea, BioAmber (BIOA) and CJ CheilJedang Corporation signed a LOI for a joint venture in China to produce up to 36,000 metric tons of bio-succinic acid per year. It’s not a greenfield. The CJCJ JV involves a retrofit of an existing fermentation plant in a market that BioAmber cannot readily penetrate today. How is BioAmber able to convert this plant? It comes down to a low pH yeast, which allows us to leverage CJCJ’s existing fermenters and purification equipment. The retrofit will allow the partners to bring this capacity on line quickly,...

Amyris’ Mysterious Partner

Jim Lane In California, Amyris (AMRS) has a new partner, described fetchingly yet with near-to-complete vagueness as a “a leader in food ingredients and nutraceuticals” which is roughly as helpful as describing a person as “someone who enjoys ice cream”. Some ice cream there is, nevertheless, in this agreement, which will bring a short-term collaboration investment of $10 million, an equity investment of up to $20 million at $1.40 per share, and $100 million in annual revenue starting in 2017 connected to the production and cost improvement of fermentation molecules. One thing, and the only one, we discover...